logo
logo

Sensifai Health secures a seed investment led by Glen Ventures, supported by Eurêka, to advance its AI platform for early inflammatory detection, addressing a $195B healthcare market.

Jul 02, 2025•about 1 month ago

Amount Raised

$195 Million

Round Type

seed

MontrealArtificial IntelligenceHealth Care

Investors

Eurêka Investment FundGlen Ventures

Description

Glen Ventures has led a seed investment round in Sensifai Health, a Montreal-based bioconvergence startup. Sensifai's AI platform aims to detect preemptive health issues, addressing a significant gap in healthcare. Originating from research at the Research Institute of the McGill University Health Centre, its technology has been validated in a peer-reviewed study. This innovative approach may significantly reduce COPD-related hospitalizations by detecting inflammation before symptoms appear.

Company Information

Company

Sensifai Health

Location

Montreal, Quebec, Canada

About

Sensifai Health is a Canadian-Israeli Preemptive Health startup at the forefront of bioconvergence. Its AI-powered platform continuously analyzes data from wearable biometric sensors to deliver early alerts of systemic inflammation before symptoms appear. By identifying silent immune signals in vulnerable individuals, Sensifai enables timely intervention that helps prevent critical health events, reduce hospitalizations, and improve long-term outcomes.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech